title: Protection against henipavirus infection by use of recombinant adeno-associated virus-vector vaccines.
abstract: Nipah virus (NiV) and Hendra virus (HeV) are closely related, recently emerged paramyxoviruses that are capable of causing considerable morbidity and mortality in several mammalian species, including humans. Henipavirus-specific vaccines are still commercially unavailable, and development of novel antiviral strategies to prevent lethal infections due to henipaviruses is highly desirable. Here we describe the development of adeno-associated virus (AAV) vaccines expressing the NiV G protein. Characterization of these vaccines in mice demonstrated that a single intramuscular AAV injection was sufficient to induce a potent and long-lasting antibody response. Translational studies in hamsters further demonstrated that all vaccinated animals were protected against lethal challenge with NiV. In addition, this vaccine induced a cross-protective immune response that was able to protect 50% of the animals against a challenge by HeV. This study presents a new efficient vaccination strategy against henipaviruses and opens novel perspectives on the use of AAV vectors as vaccines against emergent diseases.
authors.affiliation: INSERM U758, 2Ecole Normale Supérieure de Lyon, Lyon, France.
authors.forename: Aurélie
authors.initials: A
authors.lastname: Ploquin
authors.forename: Judit
authors.initials: J
authors.lastname: Szécsi
authors.forename: Cyrille
authors.initials: C
authors.lastname: Mathieu
authors.forename: Vanessa
authors.initials: V
authors.lastname: Guillaume
authors.forename: Véronique
authors.initials: V
authors.lastname: Barateau
authors.forename: Kien Chai
authors.initials: KC
authors.lastname: Ong
authors.forename: Kum Thong
authors.initials: KT
authors.lastname: Wong
authors.forename: François-Loïc
authors.initials: FL
authors.lastname: Cosset
authors.forename: Branka
authors.initials: B
authors.lastname: Horvat
authors.forename: Anna
authors.initials: A
authors.lastname: Salvetti
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology; D045744:Cell Line, Tumor; D006224:Cricetinae; D000229:Dependovirus / Q000235:genetics*; D004195:Disease Models, Animal; D005822:Genetic Vectors / Q000235:genetics*; D045464:Henipavirus Infections / Q000276:immunology* / Q000517:prevention & control* / Q000821:virology; D006801:Humans; D056724:Immunity, Humoral; D007074:Immunoglobulin G / Q000276:immunology; D008297:Male; D051379:Mice; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology*
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D007074:Immunoglobulin G; D014614:Vaccines, Synthetic; D014765:Viral Vaccines